Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC
- Trial ID
- NCT04905316 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Published in
- New in Oncology - Oct 22, 2026
CHORUS (NCT04905316) tested canakinumab, an anti–interleukin-1β monoclonal antibody intended to blunt protumor inflammation, given with concurrent chemoradiotherapy (cCRT) and continued alongside anti–PD-L1 durvalumab consolidation in an open-label, single-arm Phase I/II study in unresectable stage III NSCLC (41 enrolled; 37 treated; prespecified efficacy population n=32). At median follow-up 25 months, 24-month PFS from RT start was 67% (95% CI 52–88) with a prespecified one-sided 90% CI lower bound of 56.5% exceeding a 46% historical benchmark; 12- and 24-month OS were 93% and 73%, and confirmed ORR was 81%. Canakinumab-related grade 3–4 AEs included neutropenia (n=5) and febrile neutropenia (n=1), with pneumonitis (any attribution) in 24% (grade 3: 2/37). For context, PACIFIC established durvalumab consolidation after chemoradiation as standard treatment, reporting approximately 56% progression-free survival at 12 months and 66.3% overall survival at 24 months. CHORUS produced encouraging results, but its 24-month PFS was measured from radiation initiation, whereas PACIFIC measured PFS from randomization after chemoradiation. Differences in patient selection, treatment timing, and study design prevent a direct comparison or any conclusion that adding canakinumab improves outcomes beyond standard chemoradiation and durvalumab.
Take home
CHORUS provides an encouraging signal that IL-1β blockade might improve outcomes when added to chemoradiation and durvalumab consolidation in unresectable stage III NSCLC. The study met its prespecified historical PFS benchmark, but its 67% two-year PFS cannot establish superiority to contemporary durvalumab-based care without randomization. Pneumonitis and hematologic toxicity remain important considerations. A controlled trial is needed to determine whether canakinumab contributes enough benefit to justify additional treatment and risk.
Source: Read the original publication
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07756645
Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC -
New trial · Nov 19, 2026 · NCT07393555
Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07874490
Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC -
New trial · Nov 12, 2026 · NCT07871214
Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC.
